Cabot (NYSE:CBT) has been assigned a $75.00 target price by equities research analysts at Northcoast Research in a report released on Monday. The firm presently has a “buy” rating on the specialty chemicals company’s stock. Northcoast Research’s price target points to a potential upside of 18.71% from the company’s current price.
Other research analysts have also recently issued research reports about the stock. KeyCorp reissued a “hold” rating on shares of Cabot in a research report on Wednesday, November 1st. Jefferies Group reissued a “buy” rating and set a $74.00 price target on shares of Cabot in a research report on Friday, November 3rd. Zacks Investment Research cut shares of Cabot from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. SunTrust Banks raised shares of Cabot from a “hold” rating to a “buy” rating in a research report on Tuesday, December 19th. Finally, ValuEngine raised shares of Cabot from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $72.33.
Shares of Cabot (CBT) traded up $1.03 during midday trading on Monday, reaching $63.18. 140,742 shares of the company traded hands, compared to its average volume of 464,317. The stock has a market cap of $3,890.00, a price-to-earnings ratio of 64.23, a PEG ratio of 1.55 and a beta of 1.24. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.02 and a current ratio of 1.63. Cabot has a 12 month low of $50.21 and a 12 month high of $68.63.
A number of institutional investors have recently made changes to their positions in the business. California Public Employees Retirement System lifted its position in Cabot by 4.4% during the 3rd quarter. California Public Employees Retirement System now owns 129,381 shares of the specialty chemicals company’s stock worth $7,219,000 after acquiring an additional 5,481 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Cabot in the third quarter valued at $330,000. New York State Common Retirement Fund lifted its holdings in shares of Cabot by 2.5% in the third quarter. New York State Common Retirement Fund now owns 454,431 shares of the specialty chemicals company’s stock valued at $25,357,000 after buying an additional 10,988 shares during the period. State Street Corp lifted its holdings in shares of Cabot by 5.1% in the second quarter. State Street Corp now owns 1,751,827 shares of the specialty chemicals company’s stock valued at $93,598,000 after buying an additional 84,905 shares during the period. Finally, Boston Partners lifted its holdings in shares of Cabot by 2.3% in the third quarter. Boston Partners now owns 218,116 shares of the specialty chemicals company’s stock valued at $12,171,000 after buying an additional 4,832 shares during the period. Institutional investors own 82.36% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Northcoast Research Reiterates “$75.00” Price Target for Cabot (CBT)” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/12/northcoast-research-reiterates-75-00-price-target-for-cabot-cbt.html.
Cabot Corporation is a global specialty chemicals and performance materials company. The Company operates through four business segments: reinforcement materials, performance chemicals, purification solutions and specialty fluids. Reinforcement materials’ rubber grade carbon blacks are used to enhance the physical properties of the systems and applications in which they are incorporated.
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.